Interferon Regulatory Factor 7 as drug development target for SLE?

Selectively reduces autoantibody producing plasma cells and downregulates type I interferon without increasing infection risk

Interferon Regulatory Factor 7 (IRF7) plays a crucial role in driving spontaneous autoimmune germinal center and plasma cell checkpoints, while being dispensable for normal responses to foreign antigens. This understanding has significant implications for the treatment of Systemic Lupus Erythematosus (SLE).

This specificity makes IRF7 an attractive therapeutic target. The goal would be to dampen the harmful autoimmune reaction characteristic of SLE without broadly suppressing the immune system and increasing vulnerability to infections. Given IRF7's role as a key regulator of type I interferon (IFN-I) production—a major driver of SLE pathogenesis—therapies that reduce IRF7 activity could decrease the excessive IFN-I levels contributing to inflammation and organ damage.

Furthermore, understanding IRF7's function deepens insights into the complex mechanisms of SLE, including how genetic variations in IRF7 contribute to disease susceptibility. The protein's influence on B cell differentiat…